REPL

$2.50-0.07 (-2.72%)

Market ClosedLast close May 1

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.

Overview Intraday ResearchPRO BacktestPRO Ask AIPRO TranscriptsPRO StatementsPRO